Lupin, Cadila Healthcare, Alembic Pharma and Sun Pharma climbed 1-3 percent intraday Thursday after these companies received approval from US Food & Drug Administration (USFDA) for various drugs.
Lupin and Alembic Pharma both got US FDA nods for antidepressant drug Desvenlafaxine Succinate while Sun Pharma's subsidiary Taro Pharma received approval for anti-allergic tablet Desloratadine.
Zydus Pharma, the subsidiary of Cadila Healthcare, has received approval from the USFDA for calcium Acetate that is used for checking high blood phosphate levels in patients who are on dialysis.
Additionally the Zydus group on Wednesday also received the market authorisation from the USFDA to market Morphine sulphate ER tablets that are used in the treatment of chronic pain or cancer related pain.
At 09:37 hours IST, the scrip of Lupin was quoting at Rs 1,882, up Rs 4.30, or 0.23 percent. Cadila Healthcare gained 1.13 percent at Rs 1,846 and Alembic Pharmaceuticals rose 2.22 percent to Rs 676. Sun Pharmaceutical Industries advanced 0.33 percent to Rs 875.90.
Posted by Sunil Shankar MatkarDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
